ABSTRACT
The prevalence of obesity is rapidly increasing worldwide and its impact on future generations must be assessed. We recently showed that colostrum from mothers with obesity contained a significantly reduced B lymphocytes (CD19+) fraction. Here, in a subsequent transversal cohort study of 48 mothers, we exhaustively characterize the B lymphocytes subsets present in peripheral blood and colostrum from obese mothers and describe a pervasive alteration of the B lymphocytes compartment of human colostrum accompanied by a dysregulated antibody composition. We describe significant decreases in regulatory B cells and soluble IgA concentrations, combined with increases in soluble IgG and double negative 2 (CD19+, CD27-, IgD-, CD38-, CD24-, CD21-, CD11c+) B lymphocytes. These alterations correlated with maternal BMI and corporal fat %. We provide evidence for possibly autoimmune IgG present in obese colostrum, and for the proinflammatory consequences of obese colostrum in vitro. Beyond the impact of obesity, we evidence the selective presence of B lymphocyte subtypes in colostrum and in situ production of IgG antibodies, which expands our current understanding of the origin of colostrum IgG. As maternal milk antibodies play a crucial role in regulating neonatal gut immune development, this work uncovers maternal obesity as a potential risk factor for compromised breastmilk immune components, calling for more research on the long-term health of lactating infants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Institute for Obesity Research and the Centro de Biotecnologia FEMSA of Tecnologico de Monterrey, and sponsored by StrainBiotech SAPI de CV.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work received approval from Ethics Committee of the Hospital Regional Materno Infantil, Servicios de Salud de Nuevo Leon, and by the IRB at the School of Medicine and Health Sciences, TecSalud, in Monterrey, Mexico (CarlMicrobio2018, Reg. No. DEISC-19 01 18 09).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
All .fcs3 files obtained as part of this work will be made freely available on FlowRepository upon paper acceptance (in process)
